Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726323 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00726323 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 74 participants.
The verdict
NCT00726323, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.
Interventions
- DRUG foretinib (formerly GSK1363089 or XL880)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2006-06-30 |
| Est. Completion | 2010-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726323
The ClinicalTrials.gov registry entry for NCT00726323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which foretinib (formerly GSK1363089 or XL880) is the first listed.
NCT00726323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726323 about?
NCT00726323 is a clinical study titled "A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)". This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classi...
What is the current status of trial NCT00726323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2006-06-30. Estimated completion is 2010-08-18.
What interventions are being tested in trial NCT00726323?
The interventions under investigation include: foretinib (formerly GSK1363089 or XL880) (DRUG).
Who is sponsoring clinical trial NCT00726323?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.